Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Study of Sibeprenlimab in Immunoglobulin A Nephropathy
NCT05248659Phase 3Enrolling by invitation
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Apr 2022
- Primary completion
- Dec 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 31
01
Overview
A Phase 3 trial of sibeprenlimab in immunoglobulin A nephropathy (IgAN), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Apr 2022; status: enrolling by invitation.
02
Drugs
sibeprenlimab
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05248659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248659.